Activin and Inhibin

Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC 50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM: K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM: K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM: K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM: K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM: K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM: K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main

Lithium ionophore I.

Neutral ionophore for a lithium ion-selective solvent polymeric membrane. (1, 2).

Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activityIn VitroLitronesib (LY2523355) is a selective Eg5 inhibitor. Litronesib (25 nM) induces cancer cells to death during mitotic arrest, and this needs

Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activityIn VitroLitronesib (LY2523355) is a selective Eg5 inhibitor. Litronesib (25 nM) induces cancer cells to death during mitotic arrest, and this needs

Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activityIn VitroLitronesib (LY2523355) is a selective Eg5 inhibitor. Litronesib (25 nM) induces cancer cells to death during mitotic arrest, and this needs